Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment.

Kim, Hyung-Don; Kim, Sun Young; Kim, Jihun; Kim, Jeong Eun; Hong, Yong Sang; Han, Buhm; Tak, Eunyoung; Ryu, Yeon-Mi; Kim, Sang-Yeob; Kim, Tae Won

Kim, Hyung-Don; Kim, Sun Young; Kim, Jihun; Kim, Jeong Eun; Hong, Yong Sang; Han, Buhm; Tak, Eunyoung; Ryu, Yeon-Mi; Kim, Sang-Yeob; Kim, Tae Won.

Afiliação

Kim HD; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43 gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Kim SY; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43 gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Kim J; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim JE; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43 gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Hong YS; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43 gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Han B; Department of BioMedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
Tak E; Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
Ryu YM; Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
Kim SY; Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
Kim TW; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43 gil, Songpa-gu, Seoul, 05505, Republic of Korea. twkimmd@amc.seoul.kr.

Sci Rep ; 12(1): 1678, 2022 01 31.

Article em En | MEDLINE | ID: mdl-35102212

Assuntos

Antineoplásicos Imunológicos/uso terapêutico; Cetuximab/uso terapêutico; Neoplasias Colorretais/tratamento farmacológico; Macrófagos Associados a Tumor/efeitos dos fármacos; Adulto; Idoso; Idoso de 80 Anos ou mais; Antígenos CD/genética; Antígenos CD/metabolismo; Antígenos de Diferenciação Mielomonocítica/genética; Antígenos de Diferenciação Mielomonocítica/metabolismo; Antineoplásicos Imunológicos/efeitos adversos; Cetuximab/efeitos adversos; Neoplasias Colorretais/genética; Neoplasias Colorretais/imunologia; Neoplasias Colorretais/metabolismo; Progressão da Doença; Feminino; Humanos; Masculino; Glicoproteínas de Membrana/genética; Glicoproteínas de Membrana/metabolismo; Pessoa de Meia-Idade; Fenótipo; Intervalo Livre de Progressão; Receptores Imunológicos/genética; Receptores Imunológicos/metabolismo; Estudos Retrospectivos; Fatores de Tempo; Transcriptoma; Microambiente Tumoral; Macrófagos Associados a Tumor/imunologia; Macrófagos Associados a Tumor/metabolismo; Adulto Jovem

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Cetuximab / Antineoplásicos Imunológicos / Macrófagos Associados a Tumor Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google